No Data
Perseus is ranked, and the performance forecast for the fiscal year ending March 2025 continues to provide clues.
Perseus <4882> has ranked (as of 9:32 AM). It has significantly continued to fall. After trading began on March 31, the previously undecided financial estimates for the fiscal year ending March 2025 were disclosed, and yesterday it hit the daily limit down. It seems that selling continues to be a factor today as well. The operating loss is estimated at 0.843 billion yen. The previous period had a loss of 0.894 billion yen. The pipeline activities for PPMX-T002 and PPMX-T003, etc. are ongoing, but as of now, there have been no leads to derivation. Volume change rate top [4
Strong performance, with an upward trend in the Dow Inc average leading to dominance in buying on dips.
[Emerging Markets Individual Stocks Global Strategy] Today's Emerging Markets are expected to show a stable development. On March 31, the US Stocks market saw the Dow Inc rise by 417.86 points (+1.00%) to 42,001.76, rebounding for the first time in four days. Caution over Trump's tariffs and the diminishing expectations of a ceasefire between Russia and Ukraine weighed on stock prices. On the other hand, the unexpected rise in the Chicago Purchasing Managers' Index and the month-end and quarter-end 'dressing buys' supported the market. Today's Emerging Markets are favorable for Buy.
Shimamura, operating profit in 25/2 increased by 7.1% to 59.2 billion yen, Financial Estimates for 26/2 increased by 2.4% to 60.6 billion yen.
The performance for the fiscal year ending February 2025 announced by Shimamura <8227> shows that revenue increased by 4.8% compared to the previous period, reaching 665.3 billion 58 million yen, and operating profit increased by 7.1%, amounting to 59.2 billion 40 million yen. In the Shimamura business, with the main private brand "CLOSSHI," products that solve customer anxieties and dissatisfaction, such as the long-lasting series "Hebirote" and the sleep space Resistance series "Minmin Lab," were sold, while enhancing the added value of the high-priced PB.
Perseus Proteomics Releases FY2025 Business Forecasts Amid Licensing Challenges
Perseus Proteomics: Notice regarding earnings forecasts for the fiscal year ending March 31, 2025
Perseus Proteomics Sees FY Parent Pretax Loss Y846.00M